Under construction – not a live service
Sign in
Taking people in FrancePhase 2

PIPE-791 tablets for people with idiopathic pulmonary fibrosis

Tests PIPE-791 against a placebo in adults with idiopathic pulmonary fibrosis.

Key facts

Who runs it
Contineum Therapeutics
Where
Amiens Cedex 1, Angers, Bobigny, Bron, Lille Cedex, Marseille, Nice, Rennes Cedex 9, and Saint-Herblain, FranceSee the 9 sitesAlso in 21 other countries, 133 sites
Registry title
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Status
Recruiting
Phase
Phase 2
People taking part
324 people, planned
Started
8 Jan 2026
Expected to end
Jun 2028
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • PIPE-791 Dose A
  • PIPE-791 Dose B
  • Placebo
Record updated
10 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 or older with idiopathic pulmonary fibrosis (IPF). They may or may not already take nintedanib or pirfenidone.

Age
40 years or older
Sex
Women and men. Women must not be able to have children.
Disease stage
IPF diagnosed within 7 years before screening. A scan (HRCT) must fit usual interstitial pneumonia (UIP) or probable UIP. Lung function (percent predicted FVC) must be 40% or higher.
Earlier treatment
Taking nintedanib or pirfenidone is allowed, but not both at the same time. Taking neither is also allowed.

Main reasons for not taking part

  • History of another interstitial lung disease besides IPF
  • Pulmonary arterial hypertension that needs more than one drug
  • IPF flare-up within 6 weeks of screening or during screening
  • Severe kidney problems (eGFR 30 ml/min/1.73 m2 or lower)
  • Moderate or severe liver impairment (Child-Pugh Class B or C)

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Male or female ≥ 40 years of age at the time of Randomization
  • A diagnosis of IPF within 7 years prior to Screening, based on the 2022 ATS/ERS/JRS/ALAT practice guideline as confirmed by the Investigator, and a centrally read screening HRCT consistent with usual interstitial pneumonia (UIP) or probable UIP
  • Percent predicted (pp) FVC ≥ 40% on Screening spirometry
  • Participants may enter the study whether or not they are receiving background nintedanib or pirfenidone therapy approved for the treatment of IPF, but not both concurrently

Who cannot take part

  • Those with a history of interstitial lung disease (ILD) other than IPF are not eligible
  • Those with pulmonary arterial hypertension (PAH) requiring multi-drug therapy are not eligible
  • Those with an estimated glomerular filtration rate (eGFR) ≤ 30 ml/min/1.73 m2 (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) (Inker 2021) or who have Child-Pugh Class B or C hepatic impairment are not eligible
  • Those who have experienced an IPF exacerbation within 6 weeks of Screening, or during Screening, are not eligible
  • Female participants must not be of childbearing potential; Additional inclusion and exclusion criteria apply

Where in France

Also in 21 other countries, 133 sites

  • Centre Hospitalier Universitaire Amiens PicardieAmiens Cedex 1, FranceTaking people
  • Centre Hospitalier Universitaire D'AngersAngers, FranceTaking people
  • Assistance Publique Hopitaux De ParisBobigny, FranceTaking people
  • Hospices Civils de LyonBron, FranceTaking people
  • Centre Hospitalier Universitaire De LilleLille Cedex, FranceTaking people
  • Centre Hospitalier Regional De MarseilleMarseille, FranceTaking people
  • Centre Hospitalier Universitaire de NiceNice, FranceTaking people
  • Centre Hospitalier Universitaire De RennesRennes Cedex 9, FranceTaking people
  • Centre Hospitalier Universitaire de NantesSaint-Herblain, FranceTaking people

About the trial

What the trial wants to find out

This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.

The 3 groups in the trial

  • PIPE-791 Dose ATreatment being tested
  • PIPE-791 Dose BTreatment being tested
  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Plain-language title
PIPE-791 tablets for people with idiopathic pulmonary fibrosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 November 2026